Page results
-
Information on how we ask for your consent to treatment, and Martha's Rule.
-
To enable us to provide a quick response when you need it most, we have developed these Frequently Asked Questions (FAQs). We kindly ask you to read through these before contacting our team as you may find the answer to your question here.
-
Your treatment for acute lymphoblastic leukaemia (ALL) will be delivered within a number of comprehensive specialised services led by medical and nursing cancer care experts.
-
The UCLH Macmillan Support and Information Service Coffee Morning — a welcoming space for anyone affected by cancer or blood conditions to connect, share experiences, and find support.
-
Acute lymphoblastic leukaemia (ALL) is a form of cancer that affects the cells in the bone marrow, the soft material inside your bones.
-
A combination of two drugs could be an effective treatment for the debilitating disease lupus, according to preliminary evidence from a UCLH led trial.
-
Your acute myeloid leukaemia (AML) treatment will be delivered within a number of comprehensive specialised services led by medical and nursing cancer care experts.
-
This page is designed to help parents/carers understand the process and what to expect during their child’s admission to the Paediatric ward.
-
Acute Myeloid Leukaemia (AML) is a form of cancer that develops in your bone marrow and affects your blood cells.
-
NHS England has published a proposed interim specification for the new services for children and young people experiencing gender dysphoria.
File results
-
FOI/2023/0192 - Non emergency patient transport - NEPTS and taxi procurement
-
FOI/2023/0187 - Treatment for urothelial and colorectal cancer
-
FOI/2023/0182 - Data privacy compliance tools
-
FOI/2023/0180 - Treatment guidelines for chronic kidney disease/ diabetic kidney disease
-
FOI/2023/0175 - Treatment for Myelofibrosis
-
FOI/2023/0174 - Integration Engine (IE) within Trust's IT estate
-
FOI/2023/0162 - ICT and Procurement strategy and organisational charts
-
FOI/2023/0132 - Renal cell carcinoma and melanoma treatment
-
FOI/2023/0139 - Meningitis and Encephalitis guidelines/ pathway
-
FOI/2023/0138 - Subject Access Requests (SARs) and Freedom of Information Requests